TCGA-CV-7430-01A-11R-2132-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.113013699
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.350
- MITOTIC_SPINDLE+0.340
- ANDROGEN_RESPONSE+0.320
- MYC_TARGETS_V2+0.320
- WNT_BETA_CATENIN_SIGNALING+0.320
- ESTROGEN_RESPONSE_EARLY+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- MTORC1_SIGNALING+0.290
- MYC_TARGETS_V1+0.290
- CHOLESTEROL_HOMEOSTASIS+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.470
- INTERFERON_GAMMA_RESPONSE-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- ANGIOGENESIS-0.270
- IL6_JAK_STAT3_SIGNALING-0.250
- KRAS_SIGNALING_UP-0.190
- MYOGENESIS-0.190
- COMPLEMENT-0.160
- INFLAMMATORY_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a82c207a-ac59-48cf-9bbf-13ff024e3f95 | — | — | 0.814 |
| 2 | B71EF25E-7DDB-42DA-84A5-920A90E85512 | — | — | 0.812 |
| 3 | TCGA-90-7769-01A-11R-2125-07 | — | cohortSQ2 | 0.810 |
| 4 | TCGA-CF-A3MG-01A-11R-A20F-07 | — | — | 0.803 |
| 5 | SRR8392895 | — | cohortSQ2 | 0.797 |
| 6 | 61C38CFD-F57F-48D2-9FC7-81776647CF0E | — | — | 0.794 |
| 7 | TCGA-18-5595-01A-01R-1635-07 | — | cohortSQ2 | 0.791 |
| 8 | 853ba3ed-7943-46df-9405-c19f0b01e8f6 | — | — | 0.788 |
| 9 | 9E2420C3-FD2A-45BB-B5A3-DC25D9F7CB3C | — | — | 0.782 |
| 10 | D1BFDB5B-3131-4B5C-8090-B3B91D4450F3 | — | — | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |